Mariam Abdelghany, Co-Founder of Clinical Oncology Pharmacy Secrets COPS shared a post on LinkedIn:
“Practice-Changing Update in ES-SCLC.
A new option is reshaping the treatment landscape of extensive-stage small cell lung cancer (ES-SCLC) after platinum failure: Tarlatamab.
What makes it different?
Tarlatamab is a bispecific T-cell engager (BiTE) targeting DLL3 – redirecting T-cells to attack SCLC cells.
Key Clinical Results (DeLLphi-301):
- Overall Response Rate: 40%
- Platinum-resistant ORR: 52%
- Platinum-sensitive ORR: 31%
- Median Duration of Response: 9.7 months.
Main toxicity BLACK -BOX warning:
Cytokine Release Syndrome CRS (mostly grade 1–2, early cycles: 51%) and neurologic toxicity like immune effector cell-associated neurotoxicity syndrome ICAN.
Careful monitoring & step-up dosing are essential.
Dose at first cycle:
- Day 1= 1mg
- Day 8 & 15= 10 mg
Frequency:
Every 2weeks from cycle 2 until progression of unacceptable toxicity.
Now recommended in NCCN for recurrent ES-SCLC after platinum ± immunotherapy.
This is a major step forward in a disease with historically limited second-line options.”
Other articles about NCCN on OncoDaily.